271 related articles for article (PubMed ID: 25456732)
1. Cost-effectiveness analysis of pharmacogenetic-guided warfarin dosing in Thailand.
Chong HY; Saokaew S; Dumrongprat K; Permsuwan U; Wu DB; Sritara P; Chaiyakunapruk N
Thromb Res; 2014 Dec; 134(6):1278-84. PubMed ID: 25456732
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of pharmacist-participated warfarin therapy management in Thailand.
Saokaew S; Permsuwan U; Chaiyakunapruk N; Nathisuwan S; Sukonthasarn A; Jeanpeerapong N
Thromb Res; 2013 Oct; 132(4):437-43. PubMed ID: 24041634
[TBL] [Abstract][Full Text] [Related]
3. Economic evaluation of pharmacogenomic-guided warfarin treatment for elderly Croatian atrial fibrillation patients with ischemic stroke.
Mitropoulou C; Fragoulakis V; Bozina N; Vozikis A; Supe S; Bozina T; Poljakovic Z; van Schaik RH; Patrinos GP
Pharmacogenomics; 2015 Jan; 16(2):137-48. PubMed ID: 25616100
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness analysis of patient self-testing therapy of oral anticoagulation.
Kantito S; Saokaew S; Yamwong S; Vathesatogkit P; Katekao W; Sritara P; Chaiyakunapruk N
J Thromb Thrombolysis; 2018 Feb; 45(2):281-290. PubMed ID: 29181693
[TBL] [Abstract][Full Text] [Related]
5. Pharmacogenetic-guided selection of warfarin versus novel oral anticoagulants for stroke prevention in patients with atrial fibrillation: a cost-effectiveness analysis.
You JH
Pharmacogenet Genomics; 2014 Jan; 24(1):6-14. PubMed ID: 24168919
[TBL] [Abstract][Full Text] [Related]
6. Cost-Utility Study of Warfarin Genotyping in the VACHS Affiliated Anticoagulation Clinic of Puerto Rico.
Martes-Martinez C; Méndez-Sepúlveda C; Millán-Molina J; French-Kim M; Marín-Centeno H; Rivera-Miranda GC; Hernández-Muñoz JJ; Duconge-Soler J
P R Health Sci J; 2017 Sep; 36(3):165-172. PubMed ID: 28915306
[TBL] [Abstract][Full Text] [Related]
7. Economic Evaluation of Direct Oral Anticoagulants Compared to Warfarin for Venous Thromboembolism in Thailand: A Cost-Utility Analysis.
Niyomsri S; Nimworapan M; Wongcharoen W; Dilokthornsakul P
Int J Environ Res Public Health; 2023 Feb; 20(4):. PubMed ID: 36833871
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of pharmacogenetic-guided dosing of warfarin in the United Kingdom and Sweden.
Verhoef TI; Redekop WK; Langenskiold S; Kamali F; Wadelius M; Burnside G; Maitland-van der Zee AH; Hughes DA; Pirmohamed M
Pharmacogenomics J; 2016 Oct; 16(5):478-84. PubMed ID: 27272045
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of pharmacogenetic-guided dosing of phenprocoumon in atrial fibrillation.
Verhoef TI; Redekop WK; Veenstra DL; Thariani R; Beltman PA; van Schie RM; de Boer A; Maitland-van der Zee AH;
Pharmacogenomics; 2013 Jun; 14(8):869-83. PubMed ID: 23746182
[TBL] [Abstract][Full Text] [Related]
10. Economic evaluation of a pharmacogenetic dosing algorithm for coumarin anticoagulants in The Netherlands.
Verhoef TI; Redekop WK; de Boer A; Maitland-van der Zee AH;
Pharmacogenomics; 2015 Jan; 16(2):101-14. PubMed ID: 25616097
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in atrial fibrillation.
Freeman JV; Zhu RP; Owens DK; Garber AM; Hutton DW; Go AS; Wang PJ; Turakhia MP
Ann Intern Med; 2011 Jan; 154(1):1-11. PubMed ID: 21041570
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of dipeptidyl peptidase-4 inhibitor monotherapy versus sulfonylurea monotherapy for people with type 2 diabetes and chronic kidney disease in Thailand.
Permsuwan U; Dilokthornsakul P; Thavorn K; Saokaew S; Chaiyakunapruk N
J Med Econ; 2017 Feb; 20(2):171-181. PubMed ID: 27645706
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of apixaban versus warfarin and aspirin in Sweden for stroke prevention in patients with atrial fibrillation.
Lanitis T; Kongnakorn T; Jacobson L; De Geer A
Thromb Res; 2014 Aug; 134(2):278-87. PubMed ID: 24935675
[TBL] [Abstract][Full Text] [Related]
14. Cost-utility analysis of transcatheter aortic valve implantation versus surgery in severe aortic stenosis patients with intermediate surgical risk in Thailand.
Permsuwan U; Yoodee V; Buddhari W; Wongpraparut N; Thonghong T; Cheewatanakornkul S; Meemook K; Sakiyalak P; Duangpakdee P; Yadee J
J Geriatr Cardiol; 2022 Nov; 19(11):822-832. PubMed ID: 36561052
[TBL] [Abstract][Full Text] [Related]
15. Cost Effectiveness of Genotype-Guided Warfarin Dosing in Patients with Mechanical Heart Valve Replacement Under the Fee-for-Service System.
Kim DJ; Kim HS; Oh M; Kim EY; Shin JG
Appl Health Econ Health Policy; 2017 Oct; 15(5):657-667. PubMed ID: 28247199
[TBL] [Abstract][Full Text] [Related]
16. Cost-Utility Analysis of Transcatheter Aortic Valve Implantation versus Surgery in High-Risk Severe Aortic Stenosis Patients in Thailand.
Permsuwan U; Yoodee V; Buddhari W; Wongpraparut N; Thonghong T; Cheewatanakornkul S; Meemook K; Sakiyalak P; Duangpakdee P; Yadee J
Clinicoecon Outcomes Res; 2022; 14():487-498. PubMed ID: 35909499
[TBL] [Abstract][Full Text] [Related]
17. Pharmacoeconomic evaluation of warfarin pharmacogenomics.
You JH
Expert Opin Pharmacother; 2011 Feb; 12(3):435-41. PubMed ID: 21231897
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness of dabigatran versus vitamin K antagonists for the prevention of stroke in patients with atrial fibrillation: a French payer perspective.
Chevalier J; Delaitre O; Hammès F; de Pouvourville G
Arch Cardiovasc Dis; 2014; 107(6-7):381-90. PubMed ID: 24973113
[TBL] [Abstract][Full Text] [Related]
19. Prolonged enoxaparin therapy to prevent venous thromboembolism after primary hip or knee replacement. A cost-utility analysis.
Haentjens P; De Groote K; Annemans L
Arch Orthop Trauma Surg; 2004 Oct; 124(8):507-17. PubMed ID: 15365714
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness of low-molecular-weight heparin for secondary prophylaxis of cancer-related venous thromboembolism.
Aujesky D; Smith KJ; Cornuz J; Roberts MS
Thromb Haemost; 2005 Mar; 93(3):592-9. PubMed ID: 15735815
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
